Aurobindo Pharma Q4 net up 2% to ₹921 cr

Aurobindo Pharma’s consolidated nett net for the March 4th roseate 2% to ₹921 crore compared to the ₹903 crore a twelvemonth earlier.

Revenue from operations of the Hyderabad-headquartered generic drugmaker accrued 5.6% to ₹8,853 crore (₹8,382 crore) adjacent arsenic U.S. formulations gross declined 13 YoY to ₹3,543 crore chiefly connected relationship of little transient sales. Bolstering the gross were Europe and Growth markets. In Europe, Aurobindo Pharma registered 30.2% summation successful gross to ₹2,795 crore (₹2,147 crore); and much than 24.7% successful Growth Markets to ₹980 crore (₹786 crore).

While full formulations gross astatine ₹7,646 crore was an summation of 4.6%, full API income was astir 13% much astatine ₹1,208 crore.

Vice-chairman and managing manager K. Nithyananda Reddy said, “We are encouraged by our show for the 4th and the year, reflecting the resilience of our concern exemplary and the spot of our extended merchandise portfolio. Consistent volumes coupled with improved operating efficiencies and disciplined execution person contributed positively to our results.”

For FY26, the nett net was level astatine ₹3,503 crore (₹3,484 crore) connected a 6.1% summation successful gross from operations to ₹33,653 crore (₹31,724 crore). The institution said its European concern crossed €1 cardinal successful revenues during the fiscal.